ONCO
Onconetix, Inc.·Healthcare
1.20
4.683%(−0.06)
Market OpenLast Updated: — ET
52W L: $0.9152W H: $382.50
ONCO NEWS
gurufocus.com
May 19
Realbotix Provides Update on Nasdaq Listing
[url="]Realbotix Corp.[/url] (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (âRealbotixâ or the âParent Companyâ), a leading AI humanoid robot manufact
globenewswire.com
May 19
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on May 21, 2026.
businesswire.com
May 19
Realbotix Provides Update on Nasdaq Listing
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a leading AI humanoid robot manufacturer for social tasks, is pleased to provide an update on its previously announced transaction to list Realbotix LLC (“RealLLC” or the “Subsidiary”), a wholly owned subsidiary of Realbotix, on the Nasdaq Capital Market via a reverse takeover transaction with Onconetix, Inc. (NASDAQ: ONCO) (“ONCO”). The proposed transaction will res.
feeds.benzinga.com
May 19
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?
Onconetix Inc. shares soared 23.65% after hours following clinical progress updates, new study initiation and developments in prostate cancer diagnostics.
globenewswire.com
May 13
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances
globenewswire.com
May 13
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
New Clinical Data Reinforce Proclarix Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances CINCINNATI, Ohio, May 13, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") today provided an update on the Q1 2026 operational progress of its fully-owned Swiss subsidiary, Proteomedix AG ("PMX"), developer of Proclarix, a CE-IVD certified diagnostic blood test used in combination with PSA (prostate-specific antigen) to identify clinically significant prostate cancer ("csPCa").
